製品名:(R)-Methyl 2-((tert-butoxycarbonyl)amino)-3-iodopropanoate

IUPAC Name:methyl (2R)-2-{[(tert-butoxy)carbonyl]amino}-3-iodopropanoate

CAS番号:93267-04-0
分子式:C9H16INO4
純度:98%
カタログ番号:CM255848
分子量:329.13

包装単位 有効在庫 価格(USD) 数量
CM255848-1000g in stock džƩǺ

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:93267-04-0
分子式:C9H16INO4
融点:-
SMILESコード:O=C(OC)[C@@H](NC(OC(C)(C)C)=O)CI
密度:
カタログ番号:CM255848
分子量:329.13
沸点:356.5°C at 760 mmHg
MDL番号:MFCD00216579
保管方法:Keep in dark place, store at 2-8°C.

Category Infos

Amino Acids and Peptides
Amino acids are organic compounds containing a basic amino group and an acidic carboxyl group. Because amino acids contain both amino and carboxyl groups, they can be polymerized in an end-to-end manner, removing a molecule of water to form a covalent amide bond or peptide bond. Many amino acids are linked together end to end to form a polypeptide. Amino acids and peptides are important components in the fields of medicine and life sciences.
amino acids wholesale
if you are finding amino acids wholesaler in china, we will be your best choose! We have our own factory, so we can give you a cheap price!

Column Infos

Selatogrel
Selatogrel is an investigational, potent, fast-acting, reversible, and highly selective P2Y12 inhibitor, being developed for the treatment of an acute myocardial infarction (AMI) in patients with a recent history of AMI. It is intended to be self-administered subcutaneously via a drug delivery system (autoinjector).
This novel, self-administered emergency agent has the potential to protect heart muscle in the very early phase of an AMI – in the crucial time between symptom onset and first medical attention – so as to treat the ongoing AMI and prevent early death.
Zetomipzomib
Kezar Life Sciences announces clinical hold of Zetomipzomib IND for treatment of lupus nephritis(LN). Zetomipzomib (KZR-616) is a selective inhibitor of the immunoproteasome currently undergoing clinical investigation in autoimmune disorders.
LN is a disease comprising a spectrum of vascular, glomerular and tubulointerstitial lesions and develops in approximately 50% of SLE patients within 10 years of their initial diagnosis. LN is associated with considerable morbidity, including an increased risk of end-stage renal disease requiring dialysis or renal transplantation and an increased risk of death. There are limited approved therapies for the treatment of LN. Management typically consists of induction therapy to achieve remission and long-term maintenance therapy to prevent relapse.

Related Products